Treatment categories for the 102 analyzed patients are divided into the renal cell cancer patients, treated with anti-PD-1 or combination therapies of anti-PD-1 with anti-CTLA-4; and the other kinds of cancer patients, treated with anti-PD-1/PD-L1 or combination therapies of anti-PD-1/PD-L1 with chemotherapy. The gene discussed is CD274; the disease is renal cell adenocarcinoma.